Literature DB >> 23686699

UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.

Jing Gao1, Jun Zhou, Yanyan Li, Ming Lu, Ru Jia, Lin Shen.   

Abstract

The aim of this study was to investigate the associations between UDP-glucuronosyltransferase (UGT) 1A1 polymorphisms and irinotecan-induced toxicities in Chinese advanced colorectal cancer patients. The genotypes of UGT1A1 6 and UGT1A1 28 were analyzed by PCR amplification and Sanger sequencing in 276 advanced colorectal cancer patients receiving irinotecan-containing chemotherapy. The influences of UGT1A1 6/28 polymorphisms on severe diarrhea and neutropenia were analyzed. The overall incidence of UGT1A1 6 and UGT1A1 28 variants was 35.5 % (GA: 28.6 %; AA: 6.9 %) and 21.0 % (TA6/TA7: 19.9 %; TA7/TA7: 1.1 %) in our cohort, respectively. A total of 16 patients (5.8 %, 16/276) had severe diarrhea and 56 patients (20.3 %, 56/276) had severe neutropenia. Neither UGT1A1 6 nor UGT1A1 28 variants were associated with severe diarrhea; however, either UGT1A1 6 (P = 0.001) or UGT1A1 28 (P = 0.029) variants were significantly associated with severe neutropenia. No differences were found between severe toxicities and clinical response in this study. Compared to western countries, Chinese patients had a distinct frequency of UGT1A1 6 or UGT1A1 28 genotypes. Both UGT1A1 6 and UGT1A1 28 variants were closely associated with irinotecan-induced severe neutropenia, but not diarrhea.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23686699     DOI: 10.1007/s12032-013-0604-x

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  29 in total

1.  Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms.

Authors:  Taroh Satoh; Takashi Ura; Yasuhide Yamada; Kentaro Yamazaki; Toshimasa Tsujinaka; Masaki Munakata; Tomohiro Nishina; Shu Okamura; Taito Esaki; Yasutsuna Sasaki; Wasaburo Koizumi; Yoshihiro Kakeji; Naoki Ishizuka; Ichinosuke Hyodo; Yuh Sakata
Journal:  Cancer Sci       Date:  2011-08-12       Impact factor: 6.716

2.  Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results.

Authors:  S R Park; S-Y Kong; J Rhee; Y-I Park; K W Ryu; J H Lee; Y-W Kim; I J Choi; C G Kim; J Y Lee; S-J Cho; N K Kim
Journal:  Ann Oncol       Date:  2010-09-22       Impact factor: 32.976

3.  Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer.

Authors:  Lucía Cortejoso; María I García; Pilar García-Alfonso; Eva González-Haba; Fernando Escolar; María Sanjurjo; Luis A López-Fernández
Journal:  Cancer Chemother Pharmacol       Date:  2013-03-31       Impact factor: 3.333

4.  UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.

Authors:  Clinton F Stewart; John C Panetta; Melinda A O'Shaughnessy; Stacy L Throm; Charles H Fraga; Thandranese Owens; Tiebin Liu; Catherine Billups; Carlos Rodriguez-Galindo; Amar Gajjar; Wayne L Furman; Lisa M McGregor
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

5.  Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study.

Authors:  Masashi Takano; Masafumi Kato; Tomoyuki Yoshikawa; Naoki Sasaki; Junko Hirata; Kenichi Furuya; Michiko Takahashi; Harushige Yokota; Nao Kino; Koji Horie; Tomoko Goto; Keiichi Fujiwara; Kenji Ishii; Yoshihiro Kikuchi; Tsunekazu Kita
Journal:  Oncology       Date:  2009-03-20       Impact factor: 2.935

6.  Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer.

Authors:  C Andreetta; C Puppin; A Minisini; F Valent; E Pegolo; G Damante; C Di Loreto; S Pizzolitto; M Pandolfi; G Fasola; A Piga; F Puglisi
Journal:  Ann Oncol       Date:  2008-09-02       Impact factor: 32.976

7.  UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan.

Authors:  Roberta Ferraldeschi; Laura J Minchell; Stephen A Roberts; Simon Tobi; Kristen D Hadfield; Fiona H Blackhall; Saifee Mullamitha; Gregory Wilson; Juan Valle; Mark Saunders; William G Newman
Journal:  Pharmacogenomics       Date:  2009-05       Impact factor: 2.533

8.  UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.

Authors:  Christoph Schulz; Volker Heinemann; Andreas Schalhorn; Nikolas Moosmann; Thomas Zwingers; Stefan Boeck; Clemens Giessen; Hans-Joachim Stemmler
Journal:  World J Gastroenterol       Date:  2009-10-28       Impact factor: 5.742

9.  Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.

Authors:  Hua Bai; Li Mao; Hang Shu Wang; Jun Zhao; Lu Yang; Tong Tong An; Xin Wang; Chun Jian Duan; Na Mei Wu; Zhi Qing Guo; Yi Xu Liu; Hong Ning Liu; Ye Yu Wang; Jie Wang
Journal:  J Clin Oncol       Date:  2009-05-04       Impact factor: 44.544

10.  UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.

Authors:  E Martinez-Balibrea; A Abad; A Martínez-Cardús; A Ginés; M Valladares; M Navarro; E Aranda; E Marcuello; M Benavides; B Massutí; A Carrato; L Layos; J L Manzano; V Moreno
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

View more
  20 in total

1.  Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan-induced toxicity in Asian cancer patients: Meta-analysis.

Authors:  Chalirmporn Atasilp; Mohitosh Biswas; Pimonpan Jinda; Nutthan Nuntharadthanaphong; Jiratha Rachanakul; Yaowaluck Hongkaew; Natchaya Vanwong; Surasak Saokaew; Chonlaphat Sukasem
Journal:  Clin Transl Sci       Date:  2022-05-31       Impact factor: 4.438

2.  Associations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patients.

Authors:  Jing Gao; Jun Zhou; Yanyan Li; Zhi Peng; Yilin Li; Xicheng Wang; Lin Shen
Journal:  Med Oncol       Date:  2013-06-20       Impact factor: 3.064

Review 3.  Colorectal cancer in Chinese patients: current and emerging treatment options.

Authors:  Leung Li; Brigette By Ma
Journal:  Onco Targets Ther       Date:  2014-10-04       Impact factor: 4.147

4.  Relationship between UGT1A1*6/*28 gene polymorphisms and the efficacy and toxicity of irinotecan-based chemotherapy.

Authors:  Yu Bai; Hai-Wei Wu; Xu Ma; Ying Liu; Yan-Hua Zhang
Journal:  Onco Targets Ther       Date:  2017-06-19       Impact factor: 4.147

5.  Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.

Authors:  Dan Liu; Jian Li; Jing Gao; Yanyan Li; Rui Yang; Lin Shen
Journal:  BMC Cancer       Date:  2017-06-20       Impact factor: 4.430

6.  Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens.

Authors:  Chen Yang; Ying Liu; Wen-qi Xi; Chen-fei Zhou; Jin-ling Jiang; Tao Ma; Zheng-bao Ye; Jun Zhang; Zheng-gang Zhu
Journal:  Drug Des Devel Ther       Date:  2015-07-17       Impact factor: 4.162

Review 7.  Role of capecitabine in treating metastatic colorectal cancer in Chinese patients.

Authors:  Feng Wang; Feng-Hua Wang; Long Bai; Rui-Hua Xu
Journal:  Onco Targets Ther       Date:  2014-04-02       Impact factor: 4.147

8.  Association between the low-dose irinotecan regimen-induced occurrence of grade 4 neutropenia and genetic variants of UGT1A1 in patients with gynecological cancers.

Authors:  Hiroyuki Moriya; Katsuhiko Saito; Nuala Helsby; Shigekazu Sugino; Michiaki Yamakage; Takeru Sawaguchi; Masahiko Takasaki; Hidenori Kato; Nahoko Kurosawa
Journal:  Oncol Lett       Date:  2014-04-08       Impact factor: 2.967

9.  Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer.

Authors:  Minmin Li; Zhehai Wang; Jun Guo; Jie Liu; Changzheng Li; Lin Liu; Huan Shi; Liyan Liu; Huihui Li; Chao Xie; Xia Zhang; Wenwen Sun; Shu Fang; Xiang Bi
Journal:  Onco Targets Ther       Date:  2014-09-23       Impact factor: 4.147

10.  The relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer.

Authors:  Xiao-Guang Xiao; Shu Xia; Man Zou; Qi Mei; Lei Zhou; Shu-Jing Wang; Yuan Chen
Journal:  Onco Targets Ther       Date:  2015-12-03       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.